Welcome to our dedicated page for CoreWeave SEC filings (Ticker: CRWV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CoreWeave, Inc. filings document the regulatory record for an AI cloud infrastructure company listed on Nasdaq with Class A common stock. The company’s 8-K reports cover operating results, customer cloud-capacity agreements, private placements of equity securities, senior notes, credit facilities, and related guarantees or collateral arrangements.
Proxy materials disclose annual meeting matters, stockholder voting items, board governance, executive compensation, and equity-award information. Capital-structure filings describe senior unsecured notes due 2031, subsidiary guarantees, private placement registration rights, and debt facilities used to finance GPU servers and related infrastructure for customer contracts.
Magnetar Financial LLC and affiliated entities disclosed multiple sales of Class A common stock of CoreWeave, Inc. (CRWV) on 09/30/2025, with weighted‑average sale prices reported in ranges from $136.94 to $142.25. After the reported transactions the group reports beneficial ownership of 9,202,863 shares on an indirect basis. The filing also shows a series of paired call and put options (a collar arrangement) written and purchased with strikes of $200 (call) and $115 (put), exercisable and expiring on 06/18/2026, in multiple lots ranging from 1,871 to 138,001 shares. The filing identifies reporting parties as Magnetar Financial, Magnetar Capital Partners LP, Supernova Management LLC and David J. Snyderman, who disclaim beneficial ownership except for pecuniary interest.
McBee Brannin, Chief Development Officer of CoreWeave, Inc. (CRWV), reported multiple transactions dated 09/30/2025. The filing shows vesting and settlement of restricted stock units (RSUs) and several sales executed under a Rule 10b5-1 trading plan adopted on May 20, 2025 to satisfy tax withholding from RSU settlements. Specific non-derivative sales include 57,903 shares at a weighted average price of $139.44 and multiple other lots with weighted-average prices ranging from $133.61 to $142.63.
The report also records acquisitions/vests of RSUs totaling 121,119 units (11,739 and 109,380) and conversions/holdings of Class B common stock that are convertible into Class A shares. Post-transaction beneficial ownership figures are reported across direct and indirect holdings, including substantial indirect Class B-based economic exposure shown in Table II.
CoreWeave, Inc. disclosed a material event relating to its lending arrangements: the company and affiliated borrower CoreWeave Compute Acquisition Co., IV, LLC executed a Fifth Amendment to the Credit Agreement dated September 29, 2025 with U.S. Bank National Association (depository bank), U.S. Bank Trust Company, National Association (administrative and collateral agent) and other lenders. The filing identifies the amendment as a reportable material event but does not include the amendment's financial terms, covenants, maturities, or other contractual details in the provided text.
The form is signed by Michael Intrator, Chief Executive Officer. Because specific changes to interest rates, borrowing capacity, repayment terms, guarantees, or other credit metrics are not disclosed in the excerpt, the practical impact on liquidity, covenant headroom, or near-term financing costs cannot be determined from the available content.
Jack D. Cogen reported beneficial ownership of 17,129,596 shares of CoreWeave, Inc. Class A common stock, representing 4.5% of the class. The filing states he has sole voting and dispositive power over 16,993,036 shares and shared voting and dispositive power over 136,560 shares. The Schedule 13G/A identifies the issuer's principal executive office in Livingston, New Jersey, and lists Cogen's business address as c/o TAG Associates LLC in New York. The filing indicates this ownership figure is below the 5% threshold that typically requires different reporting status and includes a signature dated October 1, 2025.
CoreWeave, Inc. (CRWV) Form 144 — An authorized sale notice reports an intended sale of 14,615 common shares through Morgan Stanley Smith Barney LLC with an aggregate market value of $2,000,062.75, and an approximate sale date of 10/01/2025 on NASDAQ. The shares were acquired as Founders Shares on 12/27/2023. The filing shows total outstanding shares of 370,470,348, placing the planned sale at a small fraction of outstanding stock. The document also lists multiple recent sales by related parties and entities during August–September 2025, including several 10b5-1 plan transactions and substantial gross proceeds reported.
Form 144 notice for CoreWeave, Inc. (CRWV): The filer notified intent to sell 14,615 shares of common stock, with an aggregate market value of $2,000,062.75, from a total of 370,470,348 shares outstanding. The proposed sale is listed for 10/01/2025 on NASDAQ. The shares were acquired as Founders Shares from the issuer on 12/27/2023, with the acquisition and payment dated the same day. Recent reported sales by related parties or accounts over the prior three months include multiple 10b5-1 plan transactions totaling material quantities (examples: 281,250 shares on 09/17/2025 for $33,379,846.88; 281,250 on 09/03/2025 for $25,487,803.13) and individual sales by Brian Venturo (e.g., 65,593 shares on 09/30/2025 for $9,146,287.92). The filer attests to no undisclosed material adverse information.
CoreWeave, Inc. (CRWV) Form 144 shows a proposed sale of 65,593 shares of Class A common stock through Morgan Stanley, with an aggregate market value of $9,146,287.92 and an approximate sale date of 09/30/2025. The shares represent restricted stock units acquired as compensation on 09/30/2025 and were paid as compensation. The filing reports the issuer's total Class A shares outstanding as 370,470,348. The notice also discloses multiple Rule 10b5-1 sales during the prior three months by related entities totaling 925,632 shares for gross proceeds of $91,055,104.72. The filer certifies no undisclosed material adverse information as part of the signature attestation.
CoreWeave, Inc. filed a Rule 144 notice reporting a proposed sale of 78,548 Class A common shares through Morgan Stanley Smith Barney, with an aggregate market value of $10,952,733.12 and an approximate sale date of 09/30/2025. The shares were acquired the same day as restricted stock units issued as compensation. The filing also discloses multiple Rule 10b5-1 sales by related parties totaling 247,365 shares over Aug–Sep 2025, which generated gross proceeds of $28,374,033.65.
Form 144 for CoreWeave, Inc. (CRWV) discloses a proposed sale of 150,000 common shares through Morgan Stanley Smith Barney LLC, scheduled approximately for 09/30/2025 with an aggregate market value of $18,378,000.00. The filer reports these shares were acquired as Founders Shares on 11/13/2017. The filing shows numerous recent executions of 10b5-1 sales by related parties on dates in August and September 2025, each selling blocks of 250,000 and 375,000 shares with multi-million dollar gross proceeds. The filing includes the filer’s representation regarding absence of undisclosed material adverse information and references Rule 10b5-1 trading plans where indicated.
Form 144 notice for CoreWeave, Inc. (CRWV) reports a proposed sale of 157,903 common shares through Morgan Stanley Smith Barney, with an aggregate market value of $19,346,275.56, from a total of 370,470,348 shares outstanding. The approximate date of sale is 09/30/2025. The filing shows the securities to be sold consist of 100,000 founders shares acquired 11/13/2017 and 57,903 restricted stock units granted as compensation on 09/30/2025.
The notice also discloses a series of Rule 10b5-1 sales by Brannin McBee and the Brannin J. McBee 2022 IRR Trust during August and September 2025; the filing lists 12 separate 10b5-1 sale entries with individual gross proceeds shown for each trade. The filer certifies no undisclosed material adverse information and references compliance with Rule 144 and any applicable 10b5-1 plan.